Doxycycline    (DrugBank: Doxycycline)

15 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎1
23プリオン病2
28全身性アミロイドーシス3
46悪性関節リウマチ3
84サルコイドーシス1
85特発性間質性肺炎1
89リンパ脈管筋腫症2
96クローン病2
97潰瘍性大腸炎2
158結節性硬化症1
162類天疱瘡(後天性表皮水疱症を含む。)3
167マルファン症候群2
227オスラー病1
280巨大動静脈奇形(頚部顔面又は四肢病変)2
299嚢胞性線維症6

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00246324December 200327/10/2005Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple SclerosisAn Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)Multiple SclerosisDrug: Interferon beta 1a, oral doxycyclineLouisiana State University Health Sciences Center ShreveportBiogenCompleted18 Years55 YearsAll16Phase 4United States

23. プリオン病 [臨床試験数:4,薬物数:5(DrugBank:2),標的遺伝子数:0,標的パスウェイ数:0]
Searched query = "Prion disease", "Creutzfeldt-Jakob disease", "CJD", "Gerstmann-Straussler-Scheinker syndrome", "Fatal familial insomnia", "Kuru disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022233-28-IT20/06/201105/03/2012Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individuals Subjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation
MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: BASSADO
INN or Proposed INN: DOXYCYCLINE HYCLATE
IST. DI RICERCHE FARMACOLOG. M. NEGRINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2EUCTR2006-001858-27-IT21/06/200612/04/2007A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - NDA randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease. - ND Creutzfeldt-Jakob Disease.
MedDRA version: 9.1Level: LLTClassification code 10011384Term: Creutzfeldt-Jakob disease
Trade Name: BASSADO 10CPS 100MG
INN or Proposed INN: Doxycycline
ISTITUTO NEUROLOGICO CARLO BESTANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy

28. 全身性アミロイドーシス [臨床試験数:212,薬物数:234(DrugBank:72),標的遺伝子数:54,標的パスウェイ数:170
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 212 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002210-31-DE31/05/201924/01/2019An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapyA randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunction of the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specifyAmyloid Center - Biotechnology Research Laboratories Policlinico San MatteoNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
120 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): yes Therapeut1c use (Phase 4): noCanada;Turkey;Germany
2NCT03474458February 11, 201916/3/2018A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyA Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based TherapyCardiac AL AmyloidosisDrug: Doxycycline;Drug: Standard of care therapyIRCCS Policlinico S. MatteoNULLRecruiting18 YearsN/AAll120Phase 2/Phase 3Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
3NCT02207556October 1, 201423/7/2014Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis TrialDoxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) AmyloidosisPrimary Systemic AmyloidosisDrug: DoxycyclineMedical College of WisconsinNULLActive, not recruiting18 YearsN/AAll32Phase 2United States

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03194204October 1, 201910/6/2017Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled TrialEfficacy of Doxycycline as a Combination Therapy in the Treatment of Rheumatoid ArthritisRheumatoid ArthritisDrug: Doxycycline TabletsAssiut UniversityNULLCompleted18 Years60 YearsAll160N/AEgypt
2ChiCTR-OPB-150072842015-10-302015-10-26Characterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patientsCharacterization of linkage between symbiotic gut microbes and fatty acid metabolism in rheumatoid arthritis patients Rheumatoid ArthritisRA group1:Doxycycline;RA group 2:Placebo;Hong Kong Baptist UniversityNULLRecruiting1880BothRA group1:20;RA group 2:20;China
3NCT01198509January 20108/9/2010Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)Rheumatoid Arthritis;Psoriatic Arthritis;Periodontal DiseaseDrug: doxycycline;Drug: vancomycinNew York University School of MedicineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Memorial Sloan Kettering Cancer CenterCompleted18 Years70 YearsAll178N/AUnited States

84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 143 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN0000259362017/06/1220/02/2017Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial Cardiac sarcoidosiscombination therapy group:
Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
Antimicrobial agent; Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy.

Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
National cerebral and cardiovascular centerNULLRecruiting20years-oldNot applicableMale and Female80Not selectedJapan

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02759120March 22, 201728/4/2016CleanUP IPF for the Pulmonary Trials CooperativeStudy of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisDrug: Antimicrobial therapy: Co-trimoxazole or Doxycycline;Other: No Intervention: Standard of CareWeill Medical College of Cornell UniversityDuke Clinical Research Institute;University of Chicago;University of Washington;University of Pittsburgh;National Heart, Lung, and Blood Institute (NHLBI)Terminated40 YearsN/AAll509Phase 3United States

89. リンパ脈管筋腫症 [臨床試験数:38,薬物数:42(DrugBank:19),標的遺伝子数:26,標的パスウェイ数:134
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 38 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00989742July 20092/10/2009Doxycycline In Lymphangioleiomyomatosis (LAM)A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.Lymphangioleiomyomatosis;Tuberous SclerosisDrug: Doxycycline;Drug: PlaceboUniversity of NottinghamNULLCompleted18 YearsN/AFemale24Phase 4United Kingdom
2EUCTR2007-003745-32-GB12/12/200826/11/2010A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAMA randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM Lymphangioleiomyomatosis
MedDRA version: 9.1Level: LLTClassification code 10049459Term: Lymphangioleiomyomatosis
MedDRA version: 9.1Level: PTClassification code 10049459Term: Lymphangioleiomyomatosis
Trade Name: Doxycycline 100 mg Capsules
INN or Proposed INN: doxycycline
University of NottinghamNULLNot RecruitingFemale: yes
Male: no
United Kingdom

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01783106February 1, 201431/1/2013Antibiotics and Hydroxychloroquine in Crohn'sA Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's DiseaseCrohn's DiseaseDrug: Ciprofloxacin;Drug: Doxycycline;Drug: Hydroxychloroquine;Drug: BudesonideRoyal Liverpool University HospitalNational Association for Colitis and Crohn's Disease;National Institute for Health Research, United KingdomCompleted18 YearsN/AAll59Phase 2United Kingdom
2EUCTR2008-001137-99-GB28/04/200927/11/2008 CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease Crohn's Disease
MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders
Royal Liverpool & Broadgreen University Hospitals TrustUniversity of LiverpoolNot Recruiting Female: yes
Male: yes
100 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noUnited Kingdom

97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02606032May 201613/11/2015Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative ColitisRandomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative ColitisUlcerative ColitisDrug: Metronidazole;Drug: Doxycycline;Drug: Terbinafine;Drug: PlaceboHamilton Health Sciences CorporationHamilton Academic Health Sciences OrganizationRecruiting18 YearsN/AAll80Phase 2Canada
2NCT00355602July 200621/7/2006Antibiotics for the Treatment of Ulcerative ColitisUse of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis PatientsColitis, UlcerativeDrug: Cefuroxime;Drug: Ciprofloxacin;Drug: Clarithromycin;Drug: Cotrimoxazole;Drug: Coamoxiclav;Drug: metronidazole;Drug: neomycin;Drug: rifaximin;Drug: Vancomycin;Drug: DoxycyclineUniversity of DundeeTenovus ScotlandCompleted18 Years79 YearsBoth40N/AUnited Kingdom

158. 結節性硬化症 [臨床試験数:100,薬物数:62(DrugBank:16),標的遺伝子数:35,標的パスウェイ数:115
Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 100 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00989742July 20092/10/2009Doxycycline In Lymphangioleiomyomatosis (LAM)A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.Lymphangioleiomyomatosis;Tuberous SclerosisDrug: Doxycycline;Drug: PlaceboUniversity of NottinghamNULLCompleted18 YearsN/AFemale24Phase 4United Kingdom

162. 類天疱瘡(後天性表皮水疱症を含む。) [臨床試験数:70,薬物数:117(DrugBank:46),標的遺伝子数:30,標的パスウェイ数:128
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 70 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02837965April 201324/6/2016Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous PemphigoidMulticenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous PemphigoidBullous PemphigoidDrug: treatment with topical superpotent corticosteroid therapy;Drug: treatment with systemic therapy (methotrexate);Drug: treatment systemic therapy (prednisone);Drug: treatment with systemic therapy (prednisone);Drug: treatment with systemic therapy (doxycycline)CHU de ReimsNULLRecruiting18 YearsN/ABoth150N/AFrance
2EUCTR2007-006658-24-DE16/12/200908/09/2009A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines StudyA randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year.
MedDRA version: 9.1Level: LLTClassification code 10006568Term: Bullous pemphigoid NOS
MedDRA version: 9.1Level: LLTClassification code 10006567Term: Bullous pemphigoid
Product Name: prednisolone
INN or Proposed INN: prednisolone
Product Name: doxycycline
INN or Proposed INN: doxycycline
Universitätsklinikum Schleswig-HolsteinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
256United Kingdom;Germany
3EUCTR2007-006658-24-GB05/03/200922/10/2008 A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year.
MedDRA version: 14.0 Level: LLT Classification code 10006568 Term: Bullous pemphigoid NOS System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.0 Level: LLT Classification code 10006567 Term: Bullous pemphigoid System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
University of NottinghamNULLNot Recruiting Female: yes
Male: yes
256 Human pharmacology (Phase 1): Therapeut1c exploratory (Phase 2): Therapeut1c conf1rmatory - (Phase 3): Therapeut1c use (Phase 4): yesGermany;United Kingdom

167. マルファン症候群 [臨床試験数:19,薬物数:38(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:49
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01949233October 20136/8/2013The Oxford Marfan TrialA Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance ImagingMarfan SyndromeDrug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 monthsUniversity of OxfordOxford University Hospitals NHS TrustRecruiting13 YearsN/ABoth56Phase 2United Kingdom
2EUCTR2010-023612-14-GB08/03/201320/12/2012The Oxford Marfan Trial A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 Marfan syndrome.
MedDRA version: 14.1 Level: PT Classification code 10026829 Term: Marfan's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Clinical Trials and Research GovernanceNULLNot Recruiting Female: yes
Male: yes
56 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noUnited Kingdom

227. オスラー病 [臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 49 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03397004September 12, 201821/11/2017Doxycycline for Hereditary Hemorrhagic TelangiectasiaDoxycycline Crossover Trial for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia (HHT)Drug: Doxycycline Hyclate;Drug: PlaceboSt. Michael's Hospital, TorontoBarrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences CentreRecruiting18 YearsN/AAll30Phase 2Canada

280. 巨大動静脈奇形(頚部顔面又は四肢病変) [臨床試験数:22,薬物数:26(DrugBank:13),標的遺伝子数:11,標的パスウェイ数:147
Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 22 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00783523March 200830/10/2008Influence of MMP on Brain AVM HemorrhageInfluence of Matrix Metalloproteinase on Brain Arteriovenous Malformation HemorrhageArteriovenous Malformations;Cavernous Angiomas;Brain AneurysmsDrug: Doxycycline or PlaceboUniversity of California, San FranciscoNULLCompleted13 YearsN/ABoth33Phase 1United States
2NCT00243893July 200424/10/2005Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsTetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsAneurysms;Arteriovenous MalformationsDrug: minocycline;Drug: doxycyclineUniversity of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Completed13 Years80 YearsBoth26Phase 1United States

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01594827October 20127/5/2012Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)Persistent MRSA Eradication Protocol (PMEP)Cystic FibrosisDrug: Inhaled Vancomycin;Drug: Placebo (Sterile Water);Drug: Rifampin;Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX);Drug: Doxycycline;Drug: Mupirocin Intranasal Creme;Drug: 4% chlorhexidine gluconate liquid skin cleanserJohns Hopkins UniversityCase Western Reserve University;Cystic Fibrosis FoundationCompleted12 YearsN/AAll29Phase 2United States
2NCT01112059November 200820/4/2010Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) PatientsA Randomized Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult CF Patients Hospitalized for Pulmonary ExacerbationsCystic FibrosisDrug: Doxycycline;Other: placeboUniversity of Alabama at BirminghamCystic Fibrosis Foundation TherapeuticsCompleted19 YearsN/AAll40N/AUnited States
3NCT01323101April 200815/2/2011Doxycycline Effects on Inflammation in Cystic FibrosisEffect of Doxycycline on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Patients With Cystic Fibrosis.Cystic FibrosisDrug: Doxycycline;Other: No doxycyclineUniversity of Southern CaliforniaNULLCompleted18 YearsN/AAll21Phase 4United States
4EUCTR2019-003501-10-NO29/05/2020Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a phase 4 multicenter randomized controlled study.Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a phase 4 multicenter randomized controlled study. - MBWtodetectPEXinCF Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Amoxicillin
Product Name: Amoxicillin
INN or Proposed INN: AMOXICILLIN
Trade Name: Amoxicillin and Clavulanic acid
Product Name: Augmentin
INN or Proposed INN: AMOXICILLIN
INN or Proposed INN: CLAVULANIC ACID
Trade Name: Heracillin
Product Name: Heracillin
INN or Proposed INN: FLUCLOXACILLIN
Trade Name: Dicloxacillin
Product Name: Dicloxacillin
INN or Proposed INN: DICLOXACILLIN
Trade Name: Trimethoprim and Sulfamethoxazole
Product Name: Bactrim
INN or Proposed INN: Trimetoprim
Other descriptive name: TRIMETHOPRIM
INN or Proposed INN: SULFAMETHOXAZOLE
Trade Name: Clarithromycin
Product Name: Klacid
INN or Proposed INN: Klacid
Other descriptive name: CLARITHROMYCIN
Trade Name: Rifampicin
Product Name: Rimactan
INN or Proposed INN: RIFAMPICIN
Trade Name: Doxycycline
Product Name: Doxycyclin
INN or Proposed INN: DOXYCYCLINE
Product Name: Fucidin Tablets
INN or Proposed INN: Fusidin
Other descriptive name: FUSIDIC ACID
Trade Name: Ciprofloxacin
Product Name: Ciprofloxacin
INN or Proposed INN: Ciproxin
Other descriptive name: CIPROFLOXACIN
Trade Name: Linez
Vãstre Gõtalandsregionen, SwedenNULLNAFemale: yes
Male: yes
100Phase 4Denmark;Norway;Sweden
5EUCTR2019-003501-10-SE07/04/2020Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. - MBWtodetectPEXinCF Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]INN or Proposed INN: AMOXICILLIN
INN or Proposed INN: CLAVULANIC ACID
INN or Proposed INN: AMOXICILLIN
INN or Proposed INN: FLUCLOXACILLIN
INN or Proposed INN: DICLOXACILLIN
INN or Proposed INN: SULFAMETHOXAZOLE
INN or Proposed INN: Trimetoprim
Other descriptive name: TRIMETHOPRIM
INN or Proposed INN: Clarithromycin
Other descriptive name: CLARITHROMYCIN
INN or Proposed INN: RIFAMPICIN
INN or Proposed INN: DOXYCYCLINE
INN or Proposed INN: Fusidic acid
Other descriptive name: FUSIDIC ACID
INN or Proposed INN: Ciprofloxacin
Other descriptive name: CIPROFLOXACIN
INN or Proposed INN: Linezolid
Other descriptive name: LINEZOLID
INN or Proposed INN: CLINDAMYCIN
Other descriptive name: CLINDAMYCIN
INN or Proposed INN: Cefuroxim
Other descriptive name: CEFUROXIME
INN or Proposed INN: CEFALEXIN
Västra GötalandsregionenNULLNAFemale: yes
Male: yes
100Phase 4Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2019-003501-10-DK22/04/2020Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. - MBWtodetectPEXinCF Cystic fibrosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]INN or Proposed INN: AMOXICILLIN
INN or Proposed INN: CLAVULANIC ACID
INN or Proposed INN: AMOXICILLIN
INN or Proposed INN: FLUCLOXACILLIN
INN or Proposed INN: DICLOXACILLIN
INN or Proposed INN: SULFAMETHOXAZOLE
INN or Proposed INN: Trimetoprim
Other descriptive name: TRIMETHOPRIM
INN or Proposed INN: Clarithromycin
Other descriptive name: CLARITHROMYCIN
INN or Proposed INN: RIFAMPICIN
INN or Proposed INN: DOXYCYCLINE
INN or Proposed INN: Fusidic acid
Other descriptive name: FUSIDIC ACID
INN or Proposed INN: Ciprofloxacin
Other descriptive name: CIPROFLOXACIN
INN or Proposed INN: Linezolid
Other descriptive name: LINEZOLID
INN or Proposed INN: CLINDAMYCIN
Other descriptive name: CLINDAMYCIN
INN or Proposed INN: Cefuroxim
Other descriptive name: CEFUROXIME
INN or Proposed INN: CEFALEXIN
Västra GötalandsregionenNULLNAFemale: yes
Male: yes
100Phase 4Denmark;Sweden